nach oben

Erschienen in:

05.05.2020 | Commentary

SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?

Erschienen in: Inflammation Research | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Excerpt

In December 2019, a new type of coronavirus pneumonia (COVID-19) emerged in Wuhan, China, and spread rapidly all over the world, forcing the World Health Organization to officially declare on 30 January 2020, the COVID-19 as a global pandemic. Lung inflammation is the main cause of life-threatening respiratory disorders at the COVID-19 severe stage [1, 2]. …

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395:497–506.CrossRef

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.CrossRef

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.05 (pii: S0092-8674(20)30229-4).CrossRefPubMedPubMedCentral

Mirabito-Colafella KM, Uijl E, Danser AH. Interference with the Renin-Angiotensin System (RAS): classical inhibitors and novel approaches. Encycl Endocr Dis. 2019. https://doi.org/10.1016/b978-0-12-801238-3.65341-2.CrossRef

van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006;27:1217–22.CrossRef

Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ (Clin Res Ed). 2012;345:e4260.

Liu CL, Shau WY, Chang CH, Wu CS, Lai MS. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. J Epidemiol. 2013;23:344–50.CrossRef

Zhang P, Zhu L, Cai J, Lei F, Qin JJ, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020. https://doi.org/10.1161/CIRCRESAHA.120.317134.CrossRefPubMed

Ruiz-Ortega M, Rupérez M, Esteban V, Rodriguez-Vita J, Sanchez-López E, Egido J. Modulation of angiotensin II effects, a potential novel approach to inflammatory and immune diseases. Curr Med Chem. 2003;2:379–94.

10.

Li XC, Zhuo JL. Nuclear factor-kappa B as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury. Curr Opin Nephrol Hypertens. 2008;17:37–433.CrossRef

11.

Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem. 2002;277:9268–77.CrossRef

12.

Rojas A, Delgado-López F, González I, Pérez-Castro R, Romero J, Rojas I. The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal. 2013;25:609–14.CrossRef

13.

González I, Romero J, Rodríguez BL, Pérez-Castro R, Rojas A. The immunobiology of the receptor of advanced glycation end-products: trends and challenges. Immunobiology. 2013;218:790–7.CrossRef

14.

Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis. 2010;31:334–41.CrossRef

15.

Rojas A, Mercadal E, Figueroa H, Morales MA. Advanced Glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol. 2008;6:44–51.CrossRef

16.

D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol. 2010;6:352–60.CrossRef

17.

Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4:285–93.CrossRef

18.

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappa B. Diabetes. 2001;50:2792–808.CrossRef

19.

Sakaguchi M, Murata H, Aoyama Y, Hibino T, Putranto EW, Ruma IM, Inoue Y, Sakaguchi Y, Yamamoto K, Kinoshita R, et al. DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes. J Biol Chem. 2014;289:23389–40202.CrossRef

20.

Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama A, Hibino T, Kataoka K, Huh NH. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS ONE. 2011;6:e23132.CrossRef

21.

Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, Huet O, Seeber RM, Abhayawardana R, Johnstone EK, Golledge J, Wang Y, Jandeleit-Dahm KA, Cooper ME, Pfleger KD, Thomas MC. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest. 2019;129:406–21.CrossRef

22.

Oczypok EA, Perkins TN, Oury TD. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017;23:40–9.PubMedPubMedCentral

23.

Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, Mednick G, Matthay ZA, Matthay MA. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008–155.CrossRef

24.

Katsuoka F, Kawakami Y, Arai T, Imuta H, Fujiwara M, Kanma H, et al. Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem Biophys Res Commun. 1997;238:512–6.CrossRef

25.

Prasad K. AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment. Int J Angiol. 2019;28:71–9.CrossRef

26.

Nakamura K, Sakaguchi M, Matsubara H, Akagi S, Sarashina T, Ejiri K, Akazawa K, Kondo M, Nakagawa K, Yoshida M, Miyoshi T, Ogo T, Oto T, Toyooka S, Higashimoto Y, Fukami K, Ito H. Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension. PLoS ONE. 2018;13(9):e0203046.CrossRef

27.

Polverino F, Celli BR, Owen CA. COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulm Circ. 2018;8:2045894018758528.CrossRef

28.

Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor β receptor. Key role for the p66 adaptor protein Shc. J Biol Chem. 2000;275:15926–32.CrossRef

29.

Du J, Sperling LS, Marrero MB, Phillips L, Delafontaine P. G-protein and tyrosine kinase receptor cross-talk in rat aortic smooth muscle cells: thrombin- and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 1996;218:934–9.CrossRef

30.

Rojas A, Morales M, Gonzalez I, Araya P. Inhibition of RAGE axis signaling: a pharmacological challenge. Curr Drug Targets. 2019;20:340–6.CrossRef

Titel: SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
Publikationsdatum: 05.05.2020
Erschienen in: Inflammation Research / Ausgabe 7/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01353-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Correction to: Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway

CHRFAM7A reduces monocyte/macrophage migration and colony formation in vitro

SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship

Jumonji domain containing-3 (JMJD3) inhibition attenuates IL-1β-induced chondrocytes damage in vitro and protects osteoarthritis cartilage in vivo

Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation

Hydrogen attenuates sepsis-associated encephalopathy by NRF2 mediated NLRP3 pathway inactivation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin